Core Problem Statement

There is a severe lack of disease-modifying therapies for vitiligo, resulting in a heavy clinical dependence on topical steroids and JAK inhibitors. These current methods carry significant safety limitations, high long-term costs, and highly inconsistent repigmentation outcomes.

Solution Overview

A first-in-class non-steroidal topical small molecule therapy (AB1001) targeting critical immune-melanocyte pathways for durable vitiligo repigmentation. Built on a proprietary immuno-dermatology discovery platform, the solution features a strong international IP moat across distinct compound classes.

Strategic Engagement Opportunities

Ahammune's clinical-stage immuno-dermatology platform offers global pharmaceutical and specialty dermatology corporations a collaborative pathway for non-steroidal asset development, distribution, and translational research in autoimmune skin diseases.